Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Status:

Opening Soon

III

Phase

1st

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

N/A

Investigational

Product

Durvalumab

IgG1k monoclonal antibody

Treatment Arms

o Active Comparator: Arm A (control)

o Experimental: Arm B (durvalumab+placebo)

o Experimental: Arm C (durvalumab+olaparib)